BARKLEY PHARMACOLOGY ASSESSMENT PHARMACOLOGY REVIEW QUESTIONS AND CORRECT ANSWERS
(VERIFIED ANSWERS) PLUS RATIONALES 2026 Q&A | LATEST EXAM UPDATE 2026/2027.
Core Domains:
Pharmacokinetics and Pharmacodynamics
Autonomic Nervous System Pharmacology
Cardiovascular and Renal Pharmacology
Central Nervous System Pharmacology
Endocrine and Metabolic Pharmacology
Anti-infective and Chemotherapeutic Agents
Gastrointestinal and Respiratory Pharmacology
Legal, Ethical, and Prescriptive Practice Standards
Introduction
This comprehensive examination is designed to rigorously assess the candidate's mastery of core pharmacological
principles essential for safe and effective clinical practice. The assessment evaluates foundational knowledge of
drug mechanisms, therapeutic applications, adverse effect profiles, and critical pharmacokinetic parameters.
Additionally, it tests the application of this knowledge through complex clinical scenarios, regulatory compliance,
and ethical decision-making. The examination consists of multiple-choice questions that challenge recall, analysis,
and clinical reasoning, ensuring the candidate is prepared for real-world pharmacotherapeutic challenges and
advanced practice roles.
,SECTION ONE: QUESTIONS 1-100
1. A 68-year-old patient with heart failure and reduced ejection fraction is prescribed a medication that
inhibits the renin-angiotensin-aldosterone system (RAAS). Which of the following adverse effects is most
specifically associated with this drug class and is a primary reason for monitoring serum electrolyte levels?
A. Hyperkalemia
B. Hypokalemia
C. Hyponatremia
D. Hypercalcemia
🟢 A. Hyperkalemia
🔴 RATIONALE: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs)
reduce aldosterone secretion, leading to decreased renal potassium excretion and a risk of hyperkalemia. This is
a clinically significant class-specific effect, particularly in patients with renal impairment or those taking
potassium supplements. The monitoring of serum potassium is a standard of care for these agents.
2. A patient is brought to the emergency department with severe respiratory depression and miosis after an
accidental overdose. Which receptor type is primarily responsible for the toxic effects observed, and what is
the appropriate reversal agent?
A. Dopamine D2 receptors; Naloxone
B. Serotonin 5-HT3 receptors; Flumazenil
C. Mu-opioid receptors; Naloxone
D. GABA-A receptors; Naltrexone
🟢 C. Mu-opioid receptors; Naloxone
,🔴 RATIONALE: The classic triad of opioid toxicity includes respiratory depression, miosis, and decreased level
of consciousness, mediated by agonism at mu-opioid receptors. Naloxone is a pure, competitive opioid
antagonist that rapidly reverses these effects by displacing opioids from these receptors. Flumazenil is a
benzodiazepine antagonist, not an opioid antagonist.
3. A 55-year-old patient with type 2 diabetes mellitus is started on metformin. The healthcare provider
emphasizes the importance of renal function monitoring. Which of the following is the primary mechanism
by which metformin is eliminated from the body, making renal function a critical safety parameter?
A. Hepatic metabolism by CYP450 enzymes
B. Glomerular filtration and renal excretion
C. Biliary excretion as an unchanged drug
D. Metabolism by plasma esterases
🟢 B. Glomerular filtration and renal excretion
🔴 RATIONALE: Metformin is not metabolized by the liver and is excreted unchanged in the urine via
glomerular filtration and tubular secretion. Accumulation of metformin in renal impairment can lead to a rare
but serious condition, lactic acidosis. Hence, renal function monitoring with serum creatinine and estimated
glomerular filtration rate (eGFR) is essential.
4. A patient is prescribed a drug that acts as a competitive antagonist at the beta-1 adrenergic receptors.
Which of the following conditions would be a contraindication for the use of this medication?
A. Supraventricular tachycardia
B. Heart failure with reduced ejection fraction
, C. Chronic stable angina
D. Uncontrolled asthma
🟢 D. Uncontrolled asthma
🔴 RATIONALE: Non-selective beta-blockers, while the question specifies a "beta-1" antagonist, a degree of
beta-2 blockade is often present, especially at higher doses. Beta-2 receptors mediate bronchodilation.
Blockade of these receptors can cause bronchoconstriction, making non-selective beta-blockers contraindicated
in patients with asthma or COPD. Even beta-1 selective agents should be used with extreme caution.
5. A 32-year-old woman with a history of migraine headaches is prescribed sumatriptan. Which of the
following is a critical patient education point regarding the mechanism of action and the potential for
significant adverse effects?
A. It causes vasodilation of cerebral arteries to relieve the headache.
B. It is a selective serotonin reuptake inhibitor that modulates pain pathways.
C. It causes vasoconstriction of cranial arteries and should not be used in patients with coronary artery disease.
D. It is a dopamine antagonist and may cause extrapyramidal symptoms.
🟢 C. It causes vasoconstriction of cranial arteries and should not be used in patients with coronary artery
disease.
🔴 RATIONALE: Sumatriptan is a 5-HT1B/1D receptor agonist that causes vasoconstriction of intracranial and
meningeal arteries. This vasoconstrictive effect is not limited to the cerebral vasculature; it can also cause
coronary vasospasm. Therefore, it is contraindicated in patients with a history of ischemic heart disease,
uncontrolled hypertension, or Prinzmetal's angina.
(VERIFIED ANSWERS) PLUS RATIONALES 2026 Q&A | LATEST EXAM UPDATE 2026/2027.
Core Domains:
Pharmacokinetics and Pharmacodynamics
Autonomic Nervous System Pharmacology
Cardiovascular and Renal Pharmacology
Central Nervous System Pharmacology
Endocrine and Metabolic Pharmacology
Anti-infective and Chemotherapeutic Agents
Gastrointestinal and Respiratory Pharmacology
Legal, Ethical, and Prescriptive Practice Standards
Introduction
This comprehensive examination is designed to rigorously assess the candidate's mastery of core pharmacological
principles essential for safe and effective clinical practice. The assessment evaluates foundational knowledge of
drug mechanisms, therapeutic applications, adverse effect profiles, and critical pharmacokinetic parameters.
Additionally, it tests the application of this knowledge through complex clinical scenarios, regulatory compliance,
and ethical decision-making. The examination consists of multiple-choice questions that challenge recall, analysis,
and clinical reasoning, ensuring the candidate is prepared for real-world pharmacotherapeutic challenges and
advanced practice roles.
,SECTION ONE: QUESTIONS 1-100
1. A 68-year-old patient with heart failure and reduced ejection fraction is prescribed a medication that
inhibits the renin-angiotensin-aldosterone system (RAAS). Which of the following adverse effects is most
specifically associated with this drug class and is a primary reason for monitoring serum electrolyte levels?
A. Hyperkalemia
B. Hypokalemia
C. Hyponatremia
D. Hypercalcemia
🟢 A. Hyperkalemia
🔴 RATIONALE: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs)
reduce aldosterone secretion, leading to decreased renal potassium excretion and a risk of hyperkalemia. This is
a clinically significant class-specific effect, particularly in patients with renal impairment or those taking
potassium supplements. The monitoring of serum potassium is a standard of care for these agents.
2. A patient is brought to the emergency department with severe respiratory depression and miosis after an
accidental overdose. Which receptor type is primarily responsible for the toxic effects observed, and what is
the appropriate reversal agent?
A. Dopamine D2 receptors; Naloxone
B. Serotonin 5-HT3 receptors; Flumazenil
C. Mu-opioid receptors; Naloxone
D. GABA-A receptors; Naltrexone
🟢 C. Mu-opioid receptors; Naloxone
,🔴 RATIONALE: The classic triad of opioid toxicity includes respiratory depression, miosis, and decreased level
of consciousness, mediated by agonism at mu-opioid receptors. Naloxone is a pure, competitive opioid
antagonist that rapidly reverses these effects by displacing opioids from these receptors. Flumazenil is a
benzodiazepine antagonist, not an opioid antagonist.
3. A 55-year-old patient with type 2 diabetes mellitus is started on metformin. The healthcare provider
emphasizes the importance of renal function monitoring. Which of the following is the primary mechanism
by which metformin is eliminated from the body, making renal function a critical safety parameter?
A. Hepatic metabolism by CYP450 enzymes
B. Glomerular filtration and renal excretion
C. Biliary excretion as an unchanged drug
D. Metabolism by plasma esterases
🟢 B. Glomerular filtration and renal excretion
🔴 RATIONALE: Metformin is not metabolized by the liver and is excreted unchanged in the urine via
glomerular filtration and tubular secretion. Accumulation of metformin in renal impairment can lead to a rare
but serious condition, lactic acidosis. Hence, renal function monitoring with serum creatinine and estimated
glomerular filtration rate (eGFR) is essential.
4. A patient is prescribed a drug that acts as a competitive antagonist at the beta-1 adrenergic receptors.
Which of the following conditions would be a contraindication for the use of this medication?
A. Supraventricular tachycardia
B. Heart failure with reduced ejection fraction
, C. Chronic stable angina
D. Uncontrolled asthma
🟢 D. Uncontrolled asthma
🔴 RATIONALE: Non-selective beta-blockers, while the question specifies a "beta-1" antagonist, a degree of
beta-2 blockade is often present, especially at higher doses. Beta-2 receptors mediate bronchodilation.
Blockade of these receptors can cause bronchoconstriction, making non-selective beta-blockers contraindicated
in patients with asthma or COPD. Even beta-1 selective agents should be used with extreme caution.
5. A 32-year-old woman with a history of migraine headaches is prescribed sumatriptan. Which of the
following is a critical patient education point regarding the mechanism of action and the potential for
significant adverse effects?
A. It causes vasodilation of cerebral arteries to relieve the headache.
B. It is a selective serotonin reuptake inhibitor that modulates pain pathways.
C. It causes vasoconstriction of cranial arteries and should not be used in patients with coronary artery disease.
D. It is a dopamine antagonist and may cause extrapyramidal symptoms.
🟢 C. It causes vasoconstriction of cranial arteries and should not be used in patients with coronary artery
disease.
🔴 RATIONALE: Sumatriptan is a 5-HT1B/1D receptor agonist that causes vasoconstriction of intracranial and
meningeal arteries. This vasoconstrictive effect is not limited to the cerebral vasculature; it can also cause
coronary vasospasm. Therefore, it is contraindicated in patients with a history of ischemic heart disease,
uncontrolled hypertension, or Prinzmetal's angina.
